{"id":921924,"date":"2025-12-22T11:40:52","date_gmt":"2025-12-22T16:40:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/"},"modified":"2025-12-22T11:40:52","modified_gmt":"2025-12-22T16:40:52","slug":"mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/","title":{"rendered":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel"},"content":{"rendered":"<h2>\nCompany Continues to Broaden Leading Wound Product Offering<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>MARIETTA, Ga., Dec.  22, 2025  (GLOBE NEWSWIRE) &#8212; MiMedx Group, Inc. (Nasdaq: MDXG) (\u201cMIMEDX\u201d or the \u201cCompany\u201d) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit<sup>\u00ae<\/sup>-Wound Gel in the United States.<\/p>\n<p>RegenKit<sup>\u00ae<\/sup>-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company\u2019s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit<sup>\u00ae<\/sup>-Wound Gel kits, developed by Antoine Turzi and approved by FDA in 2022, are covered nationally by CMS and LCD for the treatment of diabetic chronic wounds under HCPCS code G0465.<\/p>\n<p>\u201cWith the addition of RegenKit, we are continuing to broaden our portfolio in Wound Care to offer patients and healthcare professionals an extensive assortment of proven solutions,\u201d stated Kim Moller, MIMEDX Chief Commercial Officer. \u201cWe are excited to add an autologous option to our offering, and we expect it will prove to be a highly complementary addition to our expanding suite of Wound products. This agreement, in combination with the recently announced clarity on Local Coverage Determination (LCD) implementation on Jan 1, 2026, puts MIMEDX in an incredibly strong competitive position as we prepare to enter the new year.\u201d<\/p>\n<p>\n        <strong>About Regen Lab USA LLC.<\/strong><br \/>\n        <br \/>Regen Lab USA LLC. is a leader in autologous regenerative medicine based in Jersey City, New Jersey, USA. Founded in 2003 by Antoine Turzi, Regen Lab is specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous PRP from the patient&#8217;s own blood for bedside procedures.<\/p>\n<p>\n        <strong>About MIMEDX<\/strong><br \/>\n        <br \/>MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company\u2019s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CbhmEcZ8NqNqduRZsLFRWPzYbfGzPsXEs2Yu4wZPH9OZo7_NBZVmrEO9Ir9_JVg7eFxHca1-pg2u9pgBbJNE2g==\" rel=\"nofollow\" target=\"_blank\">www.mimedx.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Matt Notarianni<br \/>Investor Relations<br \/>470-304-7291<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TWzgjCzXEqnZFRL5ANddERQDt8Hht2d3Jg5HAzfI5Gj2gPJUPhr_72GvLei_ZxcrYb-VP-Du7GUYi9DaRVzToJeLQG51YhFjFFBre0M5Xk0=\" rel=\"nofollow\" target=\"_blank\">mnotarianni@mimedx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjVlOTI2ZGMtY2RlOC00MzQzLWI0ZTItZDAzZWUxYzg4ZDQ2LTEwMjIxNTEtMjAyNS0xMi0yMi1lbg==\/tiny\/MiMedx-Group-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) &#8212; MiMedx Group, Inc. (Nasdaq: MDXG) (\u201cMIMEDX\u201d or the \u201cCompany\u201d) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit\u00ae-Wound Gel in the United States. RegenKit\u00ae-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company\u2019s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit\u00ae-Wound Gel kits, developed by &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921924","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) &#8212; MiMedx Group, Inc. (Nasdaq: MDXG) (\u201cMIMEDX\u201d or the \u201cCompany\u201d) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit\u00ae-Wound Gel in the United States. RegenKit\u00ae-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company\u2019s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit\u00ae-Wound Gel kits, developed by &hellip; Continue reading &quot;MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T16:40:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel\",\"datePublished\":\"2025-12-22T16:40:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/\"},\"wordCount\":397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/\",\"name\":\"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\",\"datePublished\":\"2025-12-22T16:40:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/","og_locale":"en_US","og_type":"article","og_title":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk","og_description":"Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) &#8212; MiMedx Group, Inc. (Nasdaq: MDXG) (\u201cMIMEDX\u201d or the \u201cCompany\u201d) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit\u00ae-Wound Gel in the United States. RegenKit\u00ae-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company\u2019s Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit\u00ae-Wound Gel kits, developed by &hellip; Continue reading \"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-22T16:40:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel","datePublished":"2025-12-22T16:40:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/"},"wordCount":397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/","name":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=","datePublished":"2025-12-22T16:40:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTk5NCM3MzMzMDc2IzIwMTA1Nzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mimedx-enters-into-exclusive-u-s-distribution-agreement-for-regenkit-wound-gel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit\u00ae-Wound Gel"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921924"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921924\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}